OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 00:01 UTC. Every row links to its source record.

SSX1 SSX family member 1

ENSG00000126752 · protein coding · Open Targets profile

Could act as a modulator of transcription (PubMed:7539744). Plays a role in spermatogenesis (PubMed:36796361). .

In 15 of 15 cancers, the evidence for SSX1 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751synovial sarcomasynovial sarcomasynovial sarcoma: somatic 0.61synovial sarcoma: germline 0.56malignant peripheral nerve sheath tumormalignant peripheral nerve sheath tumormalignant peripheral nerve sheath tumor: somatic 0.61lung carcinomalung carcinomalung carcinoma: somatic 0.61rhabdomyosarcomarhabdomyosarcomarhabdomyosarcoma: somatic 0.61undifferentiated pleomorphic sarcomaundifferentiated pleomorphic sarcomaundifferentiated pleomorphic sarcoma: somatic 0.61epithelioid sarcomaepithelioid sarcomaepithelioid sarcoma: somatic 0.61leiomyosarcomaleiomyosarcomaleiomyosarcoma: somatic 0.61neurofibromaneurofibromaneurofibroma: somatic 0.61thyroid gland spindle cell tumor with t…thyroid gland spindle cell tumor with thymus-like differentiationthyroid gland spindle cell tumor with thymus-like differentiation: somatic 0.61biphasic synovial sarcomabiphasic synovial sarcomabiphasic synovial sarcoma: somatic 0.61plexiform neurofibromaplexiform neurofibromaplexiform neurofibroma: somatic 0.61pleural sarcomatoid mesotheliomapleural sarcomatoid mesotheliomapleural sarcomatoid mesothelioma: somatic 0.61extraskeletal Ewing sarcoma/peripheral …extraskeletal Ewing sarcoma/peripheral primitive neuroectodermal tumorextraskeletal Ewing sarcoma/peripheral primitive neuroectodermal tumor: somatic 0.61liposarcomaliposarcomaliposarcoma: somatic 0.61chordomachordomachordoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
Database Ubiquitination

gnomAD loss of function constraint: o/e 3.96370005607605 (upper bound 4.932499885559082). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of SSX1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of SSX1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.